{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T05:48:08Z","timestamp":1791697688365,"version":"4.3.4"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T00:00:00Z","timestamp":1602979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T00:00:00Z","timestamp":1602979200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neuropsychopharmacol."],"published-print":{"date-parts":[[2021,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>JNJ-42165279 is a selective inhibitor of fatty acid amide hydrolase (FAAH), the enzyme responsible for the degradation of fatty acid amides (FAA) including anandamide (AEA), palmitoylethanolamide (PEA), and N-oleoylethanolamide (OEA). We assessed the efficacy, safety, tolerability, pharmacokinetics, and pharmacodynamics of treatment with JNJ-42165279 in subjects with social anxiety disorder (SAD). This was a multicenter, double-blind, placebo-controlled study randomizing subjects to 12 weeks of treatment with either JNJ-42165279 (25\u2009mg daily) or placebo (PBO). The primary endpoint was the change in the Liebowitz Social Anxiety Scale (LSAS) total score from baseline to end of study. Secondary endpoints included the Hamilton Anxiety Scale (HAM-A), Hamilton Depression Rating Scale (HDRS<jats:sub>17<\/jats:sub>), and the Clinical Global Impression-Improvement (CGI-I). Samples were collected for plasma concentration of AEA, PEA, OEA, and JNJ-42165279. A total of 149 subjects were enrolled with a mean baseline LSAS total score of 102.6 (SD 16.84). The mean change from baseline (SD) in LSAS total score at week 12 was numerically greater for JNJ-42165279: \u221229.4 (27.47) compared to PBO: \u221222.4 (23.57) but not significant. The percentage of subjects with \u226530% improvement from baseline in the LSAS total score was significantly higher for JNJ-42165279 (42.4%) compared to PBO (23.6%) (<jats:italic>p<\/jats:italic> value\u2009=\u20090.04). The percentage of subjects with a CGI-I score of much or very much improved was also significantly higher for JNJ-42165279 (44.1%) than for PBO (23.6%) (<jats:italic>p<\/jats:italic> value\u2009=\u20090.02). The drug was well tolerated. JNJ-42165279 appears to elicit an anxiolytic effect in subjects with SAD although trough concentrations with 25\u2009mg once daily appeared to be insufficient to completely inhibit FAAH activity which may have led to suboptimal efficacy. <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/ClinicalTrials.gov\">ClinicalTrials.gov<\/jats:ext-link> Identifier: NCT02432703.<\/jats:p>","DOI":"10.1038\/s41386-020-00888-1","type":"journal-article","created":{"date-parts":[[2020,10,18]],"date-time":"2020-10-18T15:02:56Z","timestamp":1603033376000},"page":"1004-1010","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":95,"title":["The effects of inhibition of fatty acid amide hydrolase (FAAH) by JNJ-42165279 in social anxiety disorder: a double-blind, randomized, placebo-controlled proof-of-concept study"],"prefix":"10.1038","volume":"46","author":[{"given":"Mark E.","family":"Schmidt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael R.","family":"Liebowitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murray B.","family":"Stein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Grunfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilse","family":"Van Hove","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0399-9003","authenticated-orcid":false,"given":"W. Kyle","family":"Simmons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Van Der Ark","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James A.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziad S.","family":"Saad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darrel J.","family":"Pemberton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Van Nueten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wayne C.","family":"Drevets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,18]]},"reference":[{"key":"888_CR1","doi-asserted-by":"publisher","first-page":"1946","DOI":"10.1126\/science.1470919","volume":"258","author":"WA Devane","year":"1992","unstructured":"Devane WA, Hanus L, Breuer A, Pertwee RG, Stevenson LA, Griffin G, et al. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 1992;258:1946\u20139.","journal-title":"Science"},{"key":"888_CR2","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.biopsych.2015.07.028","volume":"79","author":"HC Lu","year":"2016","unstructured":"Lu HC, Mackie K. An introduction to the endogenous cannabinoid system. Biol Psychiatry. 2016;79:516\u201325.","journal-title":"Biol Psychiatry"},{"key":"888_CR3","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrn1247","volume":"4","author":"D Piomelli","year":"2003","unstructured":"Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci. 2003;4:873\u201384.","journal-title":"Nat Rev Neurosci"},{"key":"888_CR4","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1021\/acsmedchemlett.5b00353","volume":"6","author":"JM Keith","year":"2015","unstructured":"Keith JM, Jones WM, Tichenor M, Liu J, Seierstad M, Palmer JA, et al. Preclinical characterization of the FAAH inhibitor JNJ-42165279. ACS Med Chem Lett. 2015;6:1204\u20138.","journal-title":"ACS Med Chem Lett"},{"key":"888_CR5","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1111\/cts.12548","volume":"11","author":"A Postnov","year":"2018","unstructured":"Postnov A, Schmidt ME, Pemberton DJ, de Hoon J, van Hecken A, van den Boer M, et al. Fatty acid amide hydrolase inhibition by JNJ-42165279: a multiple-ascending dose and a positron emission tomography study in healthy volunteers. Clin Transl Sci. 2018;11:397\u2013404.","journal-title":"Clin Transl Sci"},{"key":"888_CR6","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1017\/S0033291707001699","volume":"38","author":"AM Ruscio","year":"2008","unstructured":"Ruscio AM, Brown TA, Chiu WT, Sareen J, Stein MB, Kessler RC. Social fears and social phobia in the USA: results from the National Comorbidity Survey Replication. Psychol Med. 2008;38:15\u201328.","journal-title":"Psychol Med"},{"key":"888_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1016\/S0140-6736(08)60488-2","volume":"371","author":"MB Stein","year":"2008","unstructured":"Stein MB, Stein DJ. Social anxiety disorder. Lancet. 2008;371:1115\u201325.","journal-title":"Lancet"},{"key":"888_CR8","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S0005-7967(97)00022-3","volume":"35","author":"RM Rapee","year":"1997","unstructured":"Rapee RM, Heimberg RG. A cognitive-behavioral model of anxiety in social phobia. Behav Res Ther. 1997;35:741\u201356.","journal-title":"Behav Res Ther"},{"key":"888_CR9","doi-asserted-by":"publisher","first-page":"1179","DOI":"10.1176\/appi.ajp.162.6.1179","volume":"162","author":"SE Bruce","year":"2005","unstructured":"Bruce SE, Yonkers KA, Otto MW, Eisen JL, Weisberg RB, Pagano M, et al. Influence of psychiatric comorbidity on recovery and recurrence in generalized anxiety disorder, social phobia, and panic disorder: a 12-year prospective study. Am J Psychiatry. 2005;162:1179\u201387.","journal-title":"Am J Psychiatry"},{"key":"888_CR10","doi-asserted-by":"publisher","unstructured":"Masdrakis VG, Turic D, Baldwin DS. Anxiety Disorders. In: Baldwin DS Leonard BE, editors. Mod Trends Pharmacopsychiatry. vol 29. Basel: Karger; 2013. p. 144\u201353. https:\/\/doi.org\/10.1159\/000351960.","DOI":"10.1159\/000351960"},{"key":"888_CR11","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1176\/appi.ajp.2013.12101353","volume":"171","author":"MH Pollack","year":"2014","unstructured":"Pollack MH, Van Ameringen M, Simon NM, Worthington JW, Hoge EA, Keshaviah A, et al. A double-blind randomized controlled trial of augmentation and switch strategies for refractory social anxiety disorder. Am J Psychiatry. 2014;171:44\u201353.","journal-title":"Am J Psychiatry"},{"key":"888_CR12","doi-asserted-by":"publisher","first-page":"1125","DOI":"10.1038\/mp.2012.90","volume":"18","author":"MN Hill","year":"2013","unstructured":"Hill MN, Kumar SA, Filipski SB, Iverson M, Stuhr KL, Keith JM, et al. Disruption of fatty acid amide hydrolase activity prevents the effects of chronic stress on anxiety and amygdalar microstructure. Mol Psychiatry. 2013;18:1125\u201335.","journal-title":"Mol Psychiatry"},{"key":"888_CR13","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1038\/mp.2012.72","volume":"18","author":"O Gunduz-Cinar","year":"2013","unstructured":"Gunduz-Cinar O, MacPherson KP, Cinar R, Gamble-George J, Sugden K, Williams B, et al. Convergent translational evidence of a role for anandamide in amygdala-mediated fear extinction, threat processing and stress-reactivity. Mol Psychiatry. 2013;18:813\u201323.","journal-title":"Mol Psychiatry"},{"key":"888_CR14","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1016\/j.biopsych.2019.07.034","volume":"87","author":"LM Mayo","year":"2019","unstructured":"Mayo LM, Asratian A, Linde J, Morena M, Haataja R, Hammar V, et al. Elevated anandamide, enhanced recall of fear extinction, and attenuated stress responses following inhibition of fatty acid amide hydrolase: a randomized, controlled experimental medicine trial. Biol Psychiatry. 2019;87:538\u201347.","journal-title":"Biol Psychiatry"},{"key":"888_CR15","doi-asserted-by":"publisher","first-page":"i2727","DOI":"10.1136\/bmj.i2727","volume":"353","author":"N Moore","year":"2016","unstructured":"Moore N. Lessons from the fatal French study BIA-10-2474. BMJ. 2016;353:i2727.","journal-title":"BMJ"},{"key":"888_CR16","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1126\/science.aaf7497","volume":"356","author":"ACM van Esbroeck","year":"2017","unstructured":"van Esbroeck ACM, Janssen APA, Cognetta AB 3rd, Ogasawara D, Shpak G, van der Kroeg M, et al. Activity-based protein profiling reveals off-target proteins of the FAAH inhibitor BIA 10-2474. Science. 2017;356:1084\u20137.","journal-title":"Science"},{"key":"888_CR17","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1093\/hmg\/ddh216","volume":"13","author":"KP Chiang","year":"2004","unstructured":"Chiang KP, Gerber AL, Sipe JC, Cravatt BF. Reduced cellular expression and activity of the P129T mutant of human fatty acid amide hydrolase: evidence for a link between defects in the endocannabinoid system and problem drug use. Hum Mol Genet. 2004;13:2113\u20139.","journal-title":"Hum Mol Genet"},{"key":"888_CR18","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1017\/S0033291798007879","volume":"29","author":"RG Heimberg","year":"1999","unstructured":"Heimberg RG, Horner KJ, Juster HR, Safren SA, Brown EJ, Schneier FR, et al. Psychometric properties of the Liebowitz Social Anxiety Scale. Psychol Med. 1999;29:199\u2013212.","journal-title":"Psychol Med"},{"key":"888_CR19","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1136\/jnnp.23.1.56","volume":"23","author":"M Hamilton","year":"1960","unstructured":"Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56\u201362.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"888_CR20","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/j.2044-8341.1959.tb00467.x","volume":"32","author":"M Hamilton","year":"1959","unstructured":"Hamilton M. The assessment of anxiety states by rating. Br J Med Psychol. 1959;32:50\u20135.","journal-title":"Br J Med Psychol"},{"key":"888_CR21","unstructured":"Guy W. ECDEU assessment manual for psychopharmacology. In: Welfare UDoHEa, editor. Rockville, MD: Public Health Service Alcohol, Drug Abuse, and Mental Health Administration; 1976. p. 217\u201322."},{"key":"888_CR22","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/00004850-199606003-00015","volume":"11","author":"DV Sheehan","year":"1996","unstructured":"Sheehan DV, Harnett-Sheehan K, Raj BA. The measurement of disability. Int Clin Psychopharmacol. 1996;11:89\u201395.","journal-title":"Int Clin Psychopharmacol"},{"key":"888_CR23","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1001\/archinte.166.10.1092","volume":"166","author":"RL Spitzer","year":"2006","unstructured":"Spitzer RL, Kroenke K, Williams JB, Lowe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med. 2006;166:1092\u20137.","journal-title":"Arch Intern Med"},{"key":"888_CR24","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1192\/bjp.167.1.99","volume":"167","author":"RP Snaith","year":"1995","unstructured":"Snaith RP, Hamilton M, Morley S, Humayan A, Hargreaves D, Trigwell P. A scale for the assessment of hedonic tone the Snaith-Hamilton Pleasure Scale. Br J Psychiatry. 1995;167:99\u2013103.","journal-title":"Br J Psychiatry"},{"key":"888_CR25","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1016\/j.sleep.2008.06.003","volume":"10","author":"RP Allen","year":"2009","unstructured":"Allen RP, Kosinski M, Hill-Zabala CE, Calloway MO. Psychometric evaluation and tests of validity of the Medical Outcomes Study 12-item Sleep Scale (MOS sleep). Sleep Med. 2009;10:531\u20139.","journal-title":"Sleep Med"},{"key":"888_CR26","first-page":"321","volume":"29","author":"J Endicott","year":"1993","unstructured":"Endicott J, Nee J, Harrison W, Blumenthal R. Quality of Life Enjoyment and Satisfaction Questionnaire: a new measure. Psychopharmacol Bull. 1993;29:321\u20136.","journal-title":"Psychopharmacol Bull"},{"key":"888_CR27","doi-asserted-by":"publisher","first-page":"152","DOI":"10.4088\/JCP.v63n0211","volume":"63","author":"DJ Stein","year":"2002","unstructured":"Stein DJ, Stein MB, Pitts CD, Kumar R, Hunter B. Predictors of response to pharmacotherapy in social anxiety disorder: an analysis of 3 placebo-controlled paroxetine trials. J Clin Psychiatry. 2002;63:152\u20135.","journal-title":"J Clin Psychiatry"},{"key":"888_CR28","doi-asserted-by":"publisher","first-page":"280","DOI":"10.1007\/s00213-004-1957-9","volume":"177","author":"MB Stein","year":"2005","unstructured":"Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology. 2005;177:280\u20138.","journal-title":"Psychopharmacology"},{"key":"888_CR29","doi-asserted-by":"publisher","first-page":"638","DOI":"10.1038\/nrd3681-c1","volume":"13","author":"SR Lindborg","year":"2014","unstructured":"Lindborg SR, Persinger CC, Sashegyi A, Mallinckrodt C, Ruberg SJ. Statistical refocusing in the design of Phase II trials offers promise of increased R&D productivity. Nat Rev Drug Discov. 2014;13:638\u201340.","journal-title":"Nat Rev Drug Discov"},{"key":"888_CR30","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.brat.2014.02.004","volume":"56","author":"G Hart","year":"2014","unstructured":"Hart G, Panayi MC, Harris JA, Westbrook RF. Benzodiazepine treatment can impair or spare extinction, depending on when it is given. Behav Res Ther. 2014;56:22\u20139.","journal-title":"Behav Res Ther"},{"key":"888_CR31","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.biopsych.2012.10.012","volume":"73","author":"NS Burghardt","year":"2013","unstructured":"Burghardt NS, Sigurdsson T, Gorman JM, McEwen BS, LeDoux JE. Chronic antidepressant treatment impairs the acquisition of fear extinction. Biol Psychiatry. 2013;73:1078\u201386.","journal-title":"Biol Psychiatry"},{"key":"888_CR32","doi-asserted-by":"publisher","first-page":"708","DOI":"10.1001\/jama.280.8.708","volume":"280","author":"MB Stein","year":"1998","unstructured":"Stein MB, Liebowitz MR, Lydiard RB, Pitts CD, Bushnell W, Gergel I. Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA. 1998;280:708\u201313.","journal-title":"JAMA"},{"key":"888_CR33","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4088\/JCP.v64n0708","volume":"64","author":"MR Liebowitz","year":"2003","unstructured":"Liebowitz MR, DeMartinis NA, Weihs K, Londborg PD, Smith WT, Chung H, et al. Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry. 2003;64:785\u201392.","journal-title":"J Clin Psychiatry"},{"key":"888_CR34","doi-asserted-by":"publisher","first-page":"10.4088\/PCC.15m","DOI":"10.4088\/PCC.15m01831","volume":"17","author":"JM Careri","year":"2015","unstructured":"Careri JM, Draine AE, Hanover R, Liebowitz MR. A 12-week double-blind, placebo-controlled, flexible-dose trial of vilazodone in generalized social anxiety disorder. Prim Care Companion CNS Disord. 2015;17;10.4088\/PCC.15m01831.","journal-title":"Prim Care Companion CNS Disord"},{"key":"888_CR35","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cpr.2017.05.004","volume":"56","author":"M Asher","year":"2017","unstructured":"Asher M, Asnaani A, Aderka IM. Gender differences in social anxiety disorder: a review. Clin Psychol Rev. 2017;56:1\u201312.","journal-title":"Clin Psychol Rev"},{"key":"888_CR36","first-page":"41","volume":"9","author":"RA Sansone","year":"2012","unstructured":"Sansone RA, Sansone LA. Antidepressant adherence: are patients taking their medications? Innov Clin Neurosci. 2012;9:41\u20136.","journal-title":"Innov Clin Neurosci"},{"key":"888_CR37","doi-asserted-by":"publisher","first-page":"1151","DOI":"10.1002\/jcph.689","volume":"56","author":"TM Shiovitz","year":"2016","unstructured":"Shiovitz TM, Bain EE, McCann DJ, Skolnick P, Laughren T, Hanina A, et al. Mitigating the effects of nonadherence in clinical trials. J Clin Pharmacol. 2016;56:1151\u201364.","journal-title":"J Clin Pharmacol"},{"key":"888_CR38","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1192\/bjp.182.4.312","volume":"182","author":"TT Haug","year":"2003","unstructured":"Haug TT, Blomhoff S, Hellstrom K, Holme I, Humble M, Madsbu HP, et al. Exposure therapy and sertraline in social phobia: I-year follow-up of a randomised controlled trial. Br J Psychiatry. 2003;182:312\u20138.","journal-title":"Br J Psychiatry"}],"container-title":["Neuropsychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-00888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-00888-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-00888-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,17]],"date-time":"2021-10-17T23:28:49Z","timestamp":1634513329000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41386-020-00888-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,18]]},"references-count":38,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,4]]}},"alternative-id":["888"],"URL":"https:\/\/doi.org\/10.1038\/s41386-020-00888-1","relation":{},"ISSN":["0893-133X","1740-634X"],"issn-type":[{"value":"0893-133X","type":"print"},{"value":"1740-634X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,18]]},"assertion":[{"value":"29 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 October 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}